Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Hydrolases
Reexamination Certificate
2011-03-01
2011-03-01
Canella, Karen A (Department: 1643)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Hydrolases
C514S012200
Reexamination Certificate
active
07897147
ABSTRACT:
Methods for preventing or treating a premenstrual disorder by peripheral administration of a botulinum toxin. The botulinum toxin can be administered to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating one or more of the symptoms of a premenstrual disorder.
REFERENCES:
patent: 5437291 (1995-08-01), Pasricha et al.
patent: 5670484 (1997-09-01), Binder
patent: 5714468 (1998-02-01), Binder
patent: 5766605 (1998-06-01), Sanders et al.
patent: 5989545 (1999-11-01), Foster et al.
patent: 6063768 (2000-05-01), First
patent: 6139845 (2000-10-01), Donovan
patent: 6299893 (2001-10-01), Schwartz et al.
patent: 6306423 (2001-10-01), Donovan et al.
patent: 6312708 (2001-11-01), Donovan
patent: 6358917 (2002-03-01), Carruthers et al.
patent: 6423319 (2002-07-01), Brooks et al.
patent: 6447787 (2002-09-01), Gassner et al.
patent: 6458365 (2002-10-01), Aoki et al.
patent: 6464986 (2002-10-01), Aoki et al.
patent: 6623742 (2003-09-01), Voet
patent: 6831059 (2004-12-01), Donovan
patent: 2001/0028475 (2001-10-01), Shibahara et al.
patent: 2002/0087765 (2002-07-01), Kumar et al.
patent: 2003/0224019 (2003-12-01), O'Brien
patent: 2004/0009180 (2004-01-01), Donovan
patent: 2004/0028706 (2004-02-01), Aoki et al.
patent: 2004/0213811 (2004-10-01), Ackerman
patent: 2004/0213812 (2004-10-01), Ackerman
patent: 2004/0213813 (2004-10-01), Ackerman
patent: 2004/0213814 (2004-10-01), Ackerman
patent: 2004/0213815 (2004-10-01), Ackerman
patent: 2004/0219172 (2004-11-01), Voet
patent: 2005/0147626 (2005-07-01), Blumenfeld
patent: 101 50 415 (2001-10-01), None
patent: 10150415 (2003-05-01), None
patent: WO95/30431 (1995-11-01), None
patent: WO 03/011333 (2002-07-01), None
Johnson, Obstetrics and Gynecology, Oct. 2004, vol. 104, pp. 845-859.
Borodic et al, Expert opinion in Investigational Drugs, 2001, vol. 10, pp. 1531-1544.
Steiner (Journal of Psychiatry and Neuroscience, 2000, vol. 25, pp. 459-468).
Miller and Miller (General Psychopharmacology, 2001, vol. 35, pp. 135-149).
Roca et al, The Journal of Clinical Endocrinology and Metabolism, 2003, vol. 88, pp. 3057-3063.
Aoki K., et al,Evidence for antinociceptive activity of botulinum toxin type A in pain management, Headache Jul. 2003;43(Suppl 1):S9-S15.
Aoki K., et al,Mechanisms of the antinociceptive effect of subcutaneous Botox: Inhibition of peripheral and central nociceptive processing, Cephalalgia Sep. 2003;23(7):649.
Bhattacharya K., et al.,Novel uses of botulinum toxin type A: two case reports, Mov Disord 2000; 15(Suppl 2):51-52.
Bigalke H., et al.,Botulinum A Neurotoxin Inhibits Non-Cholinergic Synaptic Transmission in Mouse Spinal Cord Neurons in Culture, Brain Research 360;318-324:1985.
Bigalke H., et al.,Tetanus Toxin and Botulinum A Toxin Inhibit Release and Uptake of Various Transmitters, as Studied with Particulate Preparations From Rat Brain and Spinal Cord, Naunyn-Schmiedeberg's Arch Pharmacol 316;244-251:1981.
Binz T. et al.,The Complete Sequence of Botulinum Neurotoxin Type A and Comparison with Other Clostridial Neurotoxins, J Biological Chemistry 265(16);9153-9158:1990.
Blugerman G., et al.,Multiple eccrine hidrocystomas: A new therapeutic option with botulinum toxin, Dermatol Surg May 2003;29(5):557-9.
Bolay, H., et al.,Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model, Nature Medicine, vol. 8 (2); Feb. 2002: 136-142.
Boyd,Mov Disord, 10(3):376:1995.
Brann D.W. et al.,Glutamate: a major excitatory transmitter in neuroendocrine regulation, Neuroendocrinology. Mar. 1995;61(3):213-25.
Brann D.W. et al.,Role of the progesterone receptor in restrained glutamic acid decarboxylase gene expression in the hypothalamus during the preovulatory luteinizing hormone surge, Neuroendocrinology. Nov. 2002;76(5):283-9.
Brem, H., et al,Placebo-Controlled Trial of Safety and Efficacy of Intraoperative Controlled Delivery by Biodegradable Polymers of Chemotherapy for Recurrent Gliomas, Lancet 345;1008-1012:1995.
Bushara K.,Botulinum toxin and rhinorrhea, Otolaryngol Head Neck Surg 1996;114(3):507.
Campbell EM et al.,Premenstrual symptoms in general practice patients. Prevalence and treatment, J Reprod Med. Oct. 1997;42(10):637-46.
Clarke et al., Innervation of substantia nigra neurons by cholinergic afferents from the pedunculopontine nucleus in the rat. Neuroanatomical and electrophysiological evidence,Neuroscience, 23:1011-1019, 1987.
Cui M., et al.,Mechanisms of the antinociceptive effect of subcutaneous Botox: Inhibition of peripheral and central nociceptive processing, Naunyn Schmiedebergs Arch Pharmacol 2002;365 (Suppl 2):R17.
Defourny L, et al.,Estrogen modulation of neuropeptides: somatostatin, neurotensin and substance P in the ventrolateral and arcuate nuclei of the female guinea pig, Neurosci Res1999;33:223-8.
Dipiro, J.T. et al.,Pharmacotherapy: A Pathophysiologic Approach; Fourth Edition. McGraw-Hill/Appleton & Lange. 1999.
DSM-IV. Diagnostic and Statistical Manual of Mental Disorders. Paris: Masson:1996.
Durham P, et al.,Mechanism of botulinum toxin type-A inhibition of calcitonin gene-related peptide(CGRP)secretion from trigeminal nerve cells, Poster Presentation, XI Congress of the International Headache Society: Rome, Italy. Sep. 13-16, 2003.
Durham P. et al.,Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy, Headache Jan. 2004; 44(1):35-43.
Durham P.L. et al.,Regulation of calcitonin gene-related peptide secretion by a serotonergic antimigraine drug, J Neurosci. May 1, 1999;19(9):3423-9.
Endicott NA, Psychophysiological correlates of “bipolarity.”J Affect Disord. 1989;17:47-56.
Fung L. K. et al.,Pharmacokinetics of Interstitial Delivery of Carmustine 4-Hydroperoxycyclophosphamide and Paclitaxel From a Biodegradable Polymer Implant in the Monkey Brain, Cancer Research 58;672-684:1998.
Ganapathy K. et al.,Opioid-Glutamate-Nitric Oxide Connection in the Regulation of Luteinizing Hormone Secretion in the Rat, Endocrinology vol. 139, No. 3 955-960.
Gircia-Rill et al., Mesopontine neurons in schizophrenia,Neuroscience, 66(2):321-335, 1995.
German et al.,Mesopontine cholinergic and non-cholinergic neurons in schizophrenia, Neuroscience, 94(1):33-38, 1999.
Goddard GV et al.,A permanent change in brain function resulting from daily electrical stimulation, Exp Neurol. 1969;25:295-330.
Gonelle-Gispert, et al.,Biochem J1;339 (pt 1):159-65:1999.
Grady-Weliky,Premenstrual Dysporic Disorder, N Engl J Med. 2003 348;5.
Habermann E., et al.,Tetanus Toxin and Botulinum A and C Neurotoxins Inhibit Noradrenaline Release From Cultured Mouse Brain, J Neurochem 51(2);522-527:1988.
Habermann E.,Inhibition by Tetanus and Botulinum A Toxin of the release of [3H]Noradrenaline and [3H]GABA From Rat Brain Homogenate, Experientia 44;224-226:1988.
Habermann,Naunyn-Schmiedeberg's Arch. Pharmacol. 1974; 281, 47-56.
Harrison's Principles of Internal Medicine(1998), edited by Anthony Fauci et al., 14thedition, published by McGraw Hill.
Heckmann M., et al.,Botulinum toxin type A injection in the treatment of lichen simplex: An open pilot study, J Am Acad Dermatol Apr. 2002;46(4):617-9.
Hitoshi Ishikawa, et al.,Presynaptic Effects of Botulinum Toxin Type A on the Neuronally Evoked Response of Albino and Pigmented Rabbit Iris Sphincter and Dilator Muscles,Jpn J Opthalmol 2000 4;44(2):106-109.
Jahanshahi M., et al.,Psychological functioning before and after treatment of torticollis with botulinum toxin, J Neurol Neurosurg Psychiatry 1992; 55(3): 229-231.
Jankovic J. et al. (Ed.),Therapy With Botulinum Toxin, Marcel Dekker, Inc., (1994), p. 52.
Jankovic J., et al. (Ed.),Therapy With Botulinum Toxin, Marcel Dekker, Inc., (1994), p. 150.
Jost W.,Ten years' experience with botulinum toxin in anal fissure, Int J Colorectal Dis Sep. 2002;17(5):298-302.
Katsambas A., et al.,Cutaneous diseases of the foot: Unapproved treatments, Clin Dermatol Nov.-Dec. 2002;20(6):689-699.
Kerdelhue B, et al., et al.Stimulatory effect of a specific substance P antagonist(RPR 100893)of human NK1 receptor on the estradiol-induce
Abel Kenton
Allergan Inc.
Canella Karen A
Condino Debra
Nassif Claude
LandOfFree
Treatment of premenstrual disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of premenstrual disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of premenstrual disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2646811